Pharmacological interventions for ADHD: a systematic review and dose–effect network meta-analysis

The Lancet Psychiatry • June 12, 2026

Avoid routine high-dose escalation in ADHD

Across attention deficit hyperactivity disorder medicines, average symptom benefit often plateaus, while higher doses can increase stopping treatment due to side effects. *Systematic review and dose–effect network meta-analysis; Level 1a (OCEBM).

Level of evidence: Level 1a (OCEBM)

Read the full summary free

Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.